Early Notification to Act, Control, and Treat
Rapid diagnosis and treatment of infectious diseases are critical to both the patient and the broader community. ENACT (Early Notification to Act, Control, and Treat) partners with innovators to develop disruptive technologies that detect infection, prognosticate outcomes, and enable early intervention following exposures to both natural and man-made infectious threats.
Companies we have partnered with on this program to date
The programmatic vision is to upend the traditional doctor-patient paradigm by empowering patients, health-care providers, and public health organizations with early actionable health status information.
Capable of monitoring physiological changes from the user's baseline
Analyze the resulting clinical data and detect health and illness signatures in individuals
Enable high-accuracy pre-symptomatic detection of infection
Interfaces between the nervous and immune systems have been shown essential for the coordination and regulation of immune responses. Non-invasive ultrasound stimulation...
Electrochemical biosensors hold the exciting potential to integrate molecular detection with signal processing and wireless communication in a miniaturized, low-cost system...
Here, an unobtrusive, adhesive integrated electrode array for continuous monitoring of stomach electric activity is introduced. This patient-friendly, disposable peel and-stick adhesive device...
An institution is currently allowed to submit more than one abstract on behalf of investigators, or teams. There is currently no limit to the number of abstracts received by an offeror. It is recommended that an offeror submit only their best products for consideration with the potential to radically transform Health Security.
Projects completed under ENACT funding are NOT guaranteed additional funding from any government source (including ENACT).
No. The government does not suggest or requiring any specific partnerships and will not provide match-making services.
At this time host-based diagnostics are considered, but pathogen detection technologies are not considered to be within scope. Host based platforms should be targeted for use as wearables or athome, and should not be designed specifically for use in doctor's offices or clinics.
While there is no required starting TRL (technology readiness level), it is preferred that projects are close to ready for commercialization by the end of the funding period.
While FDA approval is typically not required by end of project, engagement with FDA typically is, but this depends on the proposed project.
ENACT cannot provide sample abstracts.
Yes, potential partners are free to submit more than one abstract so long as those projects are discrete, stand-alone projects.
Applicants are welcome to consult with DRIVe's Accelerator network, which provides wraparound technical and business development support services.